Autolus Therapeutics

AUTL · NASDAQ

$1.66+$0.07 (+4.40%)TodayMarket closed · Oct 20, 7:53 PM ET

Prev close $1.59

About AUTL

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. The company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Employees: 754
Headquarters: London
Listed: Jun 22, 2018
Sector: Health Care
Industry: Biotechnology
Website: autolus.com

Leadership

Autolus Therapeutics executives
Name	Title	Since	Age
Michael Bonney	—	2024	66
Christian Itin	—	2016	61
Martin Pule	—	—	52
Robert Dolski	—	—	55
Christopher Vann	—	—	60
Alexander Swan	—	—	60
Matthias Will	—	—	52
Alex Driggs	—	—	49
David Brochu	—	—	69
Miranda Neville	—	—	50
Brent Rice	—	—	59
Christopher Williams	—	—	45
Ryan Richardson	—	—	45
Robert Azelby	—	—	57
Linda Bain	—	—	54
John Berriman	—	—	77
Cynthia Butitta	—	—	70
Robert Iannone	—	—	58
Elisabeth Leiderman	—	—	48
Ravi Rao	—	—	57
William Young	—	—	80

Revenue by product and region

Fiscal year ended Dec 31, 2025: $75.39M total revenue

By product

Product revenue, net$74.32M98.6%
License revenue$1.10M1.5%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Autolus Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
AbCellera Biolog ABCL	Supplier and customer	CA	0.86
United Kingdom	Customer	GB	—
Cancer Research UK	Supplier	GB	—
King's College London	Supplier and customer	GB	—
University College London	Supplier and customer	GB	—
Syncona Portfolio Ltd.	Supplier and customer	GB	—
Miltenyi Biotec GmbH	Supplier	DE	—
Noile-Immune Biotech, Inc.	Supplier and customer	JP	—
AGC Biologics S.p.A. MLM.MI	Supplier	IT	—
PPF Group NV	Supplier and customer	NL	—

Similar companies

Companies in the same industry as Autolus Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.